Issue Date: April 8, 2013 | Web Date: April 4, 2013
Novartis Loses India Patent Fight
Novartis has lost a landmark case in the Supreme Court of India in which it sought patent protection for its cancer drug Gleevec. Applauded by nongovernmental organizations that buy generic drugs from India, the ruling is another setback for multinational drug companies that were hoping for stricter patent protection.
In its 112-page ruling, the Supreme Court decided that Gleevec’s active ingredient, imatinib mesylate in β-crystalline form, is a close derivative of . . .
To view the rest of this content, please log in with your ACS ID.
- Chemical & Engineering News
- ISSN 0009-2347
- Copyright © American Chemical Society